| Mr Alexander M Schwartz, MD | |
|
2 Centerock Rd, West Nyack, NY 10994-2215 | |
| (845) 703-6999 | |
| (845) 703-6297 |
| Full Name | Mr Alexander M Schwartz |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 27 Years |
| Location | 2 Centerock Rd, West Nyack, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275569378 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 226868 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensack Meridian Health Pascack Valley Medical | Westwood, NJ | Hospital |
| Valley Hospital | Ridgewood, NJ | Hospital |
| Nyack Hospital | Nyack, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mpv New Jersey Md Services Pc | 5991097669 | 120 |
News Archive
Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.
Results from the HEBE III study, a prospective, randomised, multicentre trial performed in seven centres in the Netherlands, suggest that the promising effects of erythropoieitin seen in previous smaller studies cannot be confirmed for the improvement of clinical outcome in patients with a first ST-elevation myocardial infarction.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
According a new study lack of sleep can actually contribute to mental health problems as suspected earlier. The study aimed to see if improvement in sleep could help reduce psychological problems such as paranoia and hallucinations. The study termed OASIS (Oxford Access for Students Improving Sleep) was a randomized controlled trial that involved 26 universities in the United Kingdom. The study was published in the latest issue of the journal Lancet Psychology.
› Verified 1 days ago
| Entity Name | Mpv New Jersey Md Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215391271 PECOS PAC ID: 5991097669 Enrollment ID: O20160718000760 |
News Archive
Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.
Results from the HEBE III study, a prospective, randomised, multicentre trial performed in seven centres in the Netherlands, suggest that the promising effects of erythropoieitin seen in previous smaller studies cannot be confirmed for the improvement of clinical outcome in patients with a first ST-elevation myocardial infarction.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
According a new study lack of sleep can actually contribute to mental health problems as suspected earlier. The study aimed to see if improvement in sleep could help reduce psychological problems such as paranoia and hallucinations. The study termed OASIS (Oxford Access for Students Improving Sleep) was a randomized controlled trial that involved 26 universities in the United Kingdom. The study was published in the latest issue of the journal Lancet Psychology.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Alexander M Schwartz, MD 155 Crystal Run Rd, Middletown, NY 10941-4028 Ph: (845) 703-6999 | Mr Alexander M Schwartz, MD 2 Centerock Rd, West Nyack, NY 10994-2215 Ph: (845) 703-6999 |
News Archive
Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.
Results from the HEBE III study, a prospective, randomised, multicentre trial performed in seven centres in the Netherlands, suggest that the promising effects of erythropoieitin seen in previous smaller studies cannot be confirmed for the improvement of clinical outcome in patients with a first ST-elevation myocardial infarction.
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
According a new study lack of sleep can actually contribute to mental health problems as suspected earlier. The study aimed to see if improvement in sleep could help reduce psychological problems such as paranoia and hallucinations. The study termed OASIS (Oxford Access for Students Improving Sleep) was a randomized controlled trial that involved 26 universities in the United Kingdom. The study was published in the latest issue of the journal Lancet Psychology.
› Verified 1 days ago
Dr. Marissa Christina Theofanides, MD Urology Medicare: May Accept Medicare Assignments Practice Location: 2 Centerock Rd, West Nyack, NY 10994 Phone: 845-703-6999 Fax: 845-703-6297 | |
Dr. Ross Bauer, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Park Dr, Suite 10, West Nyack, NY 10994 Phone: 845-354-5000 Fax: 845-354-9469 | |
Mitchell Fraiman, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 845-354-5000 Fax: 845-354-9469 | |
Kathleen Latino, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 854-354-5000 Fax: 845-354-9469 | |
Richard Evans, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 845-354-5000 Fax: 845-354-9469 | |
Richard Kroll, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Park Dr, West Nyack, NY 10994 Phone: 845-354-5000 Fax: 854-354-9469 |